8-K: Inogen Reports 8.1% Revenue Increase in Q1 2024, Driven by International and B2B Sales

Inogen's first quarter 2024 financial results show an 8.1% increase in total revenue, reaching $78.0 million, primarily due to strong international and business-to-business sales.

Summary

• Inogen's total revenue for the first quarter of 2024 increased by 8.1% to $78.0 million, up from $72.2 million in the same period last year.
• This growth was mainly driven by higher international and domestic business-to-business sales, which offset lower direct-to-consumer sales and rental revenue.
• The company's gross margin improved to 44.1% in Q1 2024, compared to 42.6% in Q1 2023, due to lower component costs.
• Operating expenses decreased by 3.8% to $50.6 million, down from $52.6 million in the first quarter of 2023.
• Inogen reported a GAAP net loss of $14.6 million for the quarter, an improvement from the $20.3 million loss in the first quarter of 2023.
• Adjusted net loss was $10.4 million, compared to $14.5 million in the first quarter of 2023.
• Adjusted EBITDA was a negative $7.6 million, an improvement from the negative $11.8 million in the first quarter of 2023.
• As of March 31, 2024, Inogen had $119.8 million in cash, cash equivalents, and marketable securities, with no debt outstanding.
• For the second quarter of 2024, Inogen expects revenue to be in the range of $81 million to $84 million.

Sentiment

Score: 7

Explanation: The sentiment is positive due to revenue growth, improved gross margin, and reduced losses, but the company is still not profitable and faces risks. The outlook is cautiously optimistic.

Positives

• The company experienced an 8.1% increase in total revenue, reaching $78.0 million.
• Gross margin improved to 44.1%, indicating better cost management.
• Operating expenses decreased by 3.8%, showing improved efficiency.
• The net loss improved from $20.3 million to $14.6 million year-over-year.
• Adjusted EBITDA improved from a negative $11.8 million to a negative $7.6 million.
• The company has a strong cash position of $119.8 million with no debt.
• Business-to-business sales, both domestic and international, showed significant growth.

Negatives

• Direct-to-consumer sales decreased by 15.6% year-over-year.
• Rental revenue decreased by 8.3% year-over-year.
• The company still reported a net loss of $14.6 million for the quarter.
• Adjusted EBITDA remains negative at $7.6 million.

Risks

• The company faces risks related to market acceptance of its products.
• Competition in the industry could impact sales and profitability.
• Interruptions or delays in the supply of components or materials could affect production.
• Seasonal variations in demand could impact revenue.
• Unanticipated increases in costs or expenses could affect profitability.
• The company faces risks associated with international operations.
• There is a risk that Inogen will not realize anticipated revenue from recent or future technology acquisitions.

Future Outlook

Inogen expects revenue to be in the range of $81 million to $84 million for the second quarter of 2024.

Management Comments

• Kevin Smith, President and Chief Executive Officer, stated that Inogen is off to a solid start in 2024.
• Management is focused on positioning the business for revenue growth, improving operating discipline, and investing in innovation.
• The company will continue executing against its strategic priorities while strengthening its market-leading position.

Industry Context

Inogen operates in the medical technology sector, specifically focusing on respiratory products for homecare. The company's performance is influenced by factors such as healthcare spending, technological advancements, and competition from other medical device manufacturers. The increase in B2B sales suggests a growing demand for their products through distributors and medical equipment providers.

Comparison to Industry Standards

• ResMed (RMD) is a major competitor in the respiratory device market, and while Inogen focuses on portable oxygen concentrators, ResMed has a broader portfolio including sleep apnea devices.
• Fisher & Paykel Healthcare (FPH) is another competitor, particularly in the area of respiratory humidification and ventilation, and has a larger global presence.
• Inogen's 8.1% revenue growth is a positive sign, but it is important to compare this to the growth rates of its competitors to assess its relative performance.
• The improvement in gross margin to 44.1% is a key indicator of efficiency, and should be compared to the gross margins of similar medical device companies.
• The negative adjusted EBITDA of $7.6 million indicates that the company is still not profitable, and this needs to be compared to the profitability of its competitors.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and improved financial performance.
• Employees may benefit from the company's focus on growth and innovation.
• Customers will continue to have access to Inogen's respiratory products.
• Suppliers may see increased demand for components and materials.
• Creditors will be reassured by the company's strong cash position and reduced losses.

Next Steps

• Inogen will host a conference call to discuss the first quarter 2024 financial results.
• The company will continue to focus on revenue growth, improving operating discipline, and investing in its innovation pipeline.
• Inogen will continue to use its Investor Relations website for disclosing material non-public information.

Key Dates

Keywords

Inogen, Respiratory Products, Medical Technology, Portable Oxygen Concentrators, Financial Results, Revenue Growth, Gross Margin, EBITDA, Net Loss, Homecare, B2B Sales, Direct-to-Consumer Sales